Short communicationAssessment of the mouse as an experimental model for studying polymorphic oxidation of the sparteine/debrisoquine type
References (16)
- et al.
The genetic polymorphism of debrisoquine/sparteine metabolism—clinical aspects
Pharmacol Ther.
(1990) - et al.
Bufuralol 1'-hydroxylase activity of the rat—strain differences and the effect of inhibitors
Biochem Pharmacol
(1986) - et al.
Antipyrine metabolism in female Lewis and Dark Agouti strains of rats, which are extensive and poor metabolisers of debrisoquine, respectively
Jap J Pharmacol
(1989) - et al.
Thiopurine methyltransferase: mouse kidney and liver assay conditions, biochemical properties and strain variation
Biochem Pharmacol
(1985) - et al.
The specificity of inhibition of debrisoquine 4-hydroxylase activity in the rat is the inverse to that in humans
Biochem Pharmacol
(1989) - et al.
Animal modelling of human polymorphic drug oxidation—the metabolism of debrisoquine and phenacetin in rat inbred strains
J Pharm Pharmacol
(1981) - et al.
Debrisoquine 4-hydroxylase: characterisation of a new P450 gene subfamily, regulation, chromosomal mapping and molecular analysis of the DA rat polymorphism
DNA
(1987) - et al.
Drug metabolising capacity of the dark agouti (DA) rat in vitro and in vivo
There are more references available in the full text version of this article.
Cited by (8)
Evidence for the catalysis of Dextromethorphan O-demethylation by a CYP2D6-like enzyme in pig liver
2000, Toxicology in VitroCitation Excerpt :An animal model for CYP2D6 has been sought but with limited success. Neither rat nor mouse forms of CYP2D reflect the human enzyme in terms of in vitro enzyme characterization, or at the primary sequence level (Adams et al., 1991; Boobis et al., 1986; Gonzalez et al., 1987; Kobayashi et al., 1989). There is some evidence that non-human primates have a form of CYP2D which is similar, but clearly not identical to human CYP2D6, as assessed by enzyme kinetic characterization and chemical inhibition studies (Wu et al., 1993).
Polymorphisms of CYP2D17 in cynomolgus and rhesus macaques: An evidence of the genetic basis for the variability of CYP2D-dependent drug metabolism
2014, Drug Metabolism and DispositionCodeine-induced hyperalgesia and allodynia: Investigating the role of glial activation
2014, Translational PsychiatryExpression, purification, and characterization of mouse CYP2D22
2006, Drug Metabolism and DispositionSelective deficiency of debrisoquine 4-hydroxylase activity in mouse liver microsomes
1997, Journal of Pharmacology and Experimental Therapeutics
- †
Present address: Addiction Research Foundation, 33 Russell Street, Toronto, Canada.
Copyright © 1991 Published by Elsevier Inc.